drugset / Trial / NCT01505530
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.
Timeline
- Start
- 2011-12
- Primary completion
- 2014-10
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LANDOGROZUMAB | Monoclonal antibody | 100 mg | Intravenous |
| Subject | LANDOGROZUMAB | Monoclonal antibody | 300 mg | Intravenous |
| Background | Erlotinib | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |